Beactica Therapeutics AB, a Swedish precision medicine company, announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which ...
The new microbiology laboratory and sterility testing suite are designed for GMP drug product applications. This addition is part of the broader Lexingt...
Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ...
CSL and Alentis Therapeutics announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which ha...
AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBM...
Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, announced positive results from a prospective, multicenter randomized controlled tr...
Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duratio...
AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its propri...
Joint venture between Reset Health and Pharmacy2U creates the first and only fully integrated national cardiometabolic care provider. Averly Health will...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, announced three-year follow-up results from the ovarian cancer cohort of its 400+ patie...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Na...
Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in partnership with Jupiter Research LLC, announced that its Que Medical Inhalation Dev...
Samfara, a European life sciences investment firm, announced that it has completed the acquisition of Chr. Olesen Synthesis from Chr. Olesen and funds mana...
Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced tha...
© 2026 Biopharma Boardroom. All Rights Reserved.
